Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program
NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Oregon Health & Science University (“OHSU”) to its Therapeutic Experience Program (TEP). This initiative will be led by Vijayshree Yadav, MD, MCR, FANA, FAAN, Professor of Neurology and OHSU Multiple Sclerosis Center Director. OHSU joins several other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (MS).
Related news for (HSDT)
- Dealmaking Drives the Tape: These Stocks Are Heating Up into the Close
- Capital Meets Conviction: VENU, HSDT, GLUE, and IHT Show Investors the Money
- MoBot alert highlights: NASDAQ: HSDT, NASDAQ: RCEL, NYSE: GPUS, NYSE: ATCH, NASDAQ: HYFT (09/15/25 06:00 AM)
- MoBot alert highlights: NYSE: ATCH, NASDAQ: HSDT, NASDAQ: HYFT, NASDAQ: HAIN, NASDAQ: BTBD (09/15/25 05:00 AM)
- Today’s Top Performers: MoBot’s Market Review 09/15/25 04:00 AM